90
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report

, , , , , , , & show all
Pages 303-307 | Published online: 25 Feb 2019

Figures & data

Figure 1 Radiographs of posterior spinal correction surgery.

Notes: She underwent posterior spinal correction surgery for scoliosis at 12 years of age. Radiographs show (A) anterior-posterior view and (B) lateral view.
Figure 1 Radiographs of posterior spinal correction surgery.

Table 1 Patient characteristics and the change of total hip bone mineral density

Table 2 Patient laboratory data

Figure 2 The change of bone turnover markers.

Notes: Serum TRACP-5b and urinary type I collagen amino-terminal telopeptide greatly decreased after the first administration. Serum bone-specific alkaline phosphatase and type I procollagen N-terminal propeptide decreased as well, while the whole-parathyroid hormone and 1-alpha, 25-dihydroxyvitamin D3 increased.
Abbreviations: BAP, bone-specific alkaline phosphatase; PINP, type I procollagen N-terminal propeptide; NTX, type I collagen amino-terminal telopeptide; TRACP-5b, tartrate-resistant acid phosphatase 5b.
Figure 2 The change of bone turnover markers.

Figure 3 The change of bone mineral density (BMD).

Notes: At 13 months of denosumab treatment, her total hip BMD T-score improved from −2.3 to −2.0, and the BMD increased by 4.5% for total hips at the end of our study. The change of femoral neck BMD was also similar.
Figure 3 The change of bone mineral density (BMD).